Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in Eur J Gastroenterol Hepatol Retrieve available abstracts of 126 articles: HTML format

Single Articles

July 2026
1. FARAH A, Mari A
   Interpretation of surgical recurrence in the dynamic phenotype of Crohn's disease.
   Eur J Gastroenterol Hepatol. 2026;38:884.
   PubMed    
   
   
   
2. BINDER IMH, Brynskov J, Attauabi M
   Chest X-ray prior to biological treatment in inflammatory bowel diseases: it is not only about tuberculosis - a case report and literature review.
   Eur J Gastroenterol Hepatol. 2026;38:836-839.
   PubMed     Abstract available
   
   
   June 2026
3. GUVEN IE
   Letter to the editor regarding 'Correlation between infliximab trough levels and postoperative endoscopic recurrence in patients with Crohn's disease'.
   Eur J Gastroenterol Hepatol. 2026;38:779.
   PubMed    
   
   
   
4. MORAES BF, Suffert LC, Cancado GGL
   Appendicectomy in active ulcerative colitis: is the evidence strong enough to support clinical recommendation? A critical appraisal.
   Eur J Gastroenterol Hepatol. 2026;38:777-778.
   PubMed    
   
   
   
5. CHEN Z, Lin X, Chen M
   Comment on 'Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study'.
   Eur J Gastroenterol Hepatol. 2026;38:774-775.
   PubMed    
   
   
   April 2026
6. XU Y, Wu K, Liu P, Ni C, et al
   Prevalence, risk factors, and clinical outcomes of extraintestinal manifestations in inflammatory bowel disease: a population-based study in china.
   Eur J Gastroenterol Hepatol. 2026 Apr 6. doi: 10.1097/MEG.0000000000003197.
   PubMed     Abstract available
   
   
   
7. FERRANTE M, Christensen B, Bressler B, Bassel M, et al
   Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with noncomplicated or complex Crohn's disease: results from the EVOLVE Expansion study.
   Eur J Gastroenterol Hepatol. 2026 Apr 6. doi: 10.1097/MEG.0000000000003193.
   PubMed     Abstract available
   
   
   
8. PRODANOVA D, Janeva A, Drobne D, Novak G, et al
   Applicator preferences for subcutaneous biologics in inflammatory bowel disease: influence on patient satisfaction and willingness to switch treatment.
   Eur J Gastroenterol Hepatol. 2026;38:455-460.
   PubMed     Abstract available
   
   
   
9. SONG T, Chen Y, Zhang C, Sun Z, et al
   Stricturing phenotype is associated with an increased risk of postoperative surgical recurrence in isolated small bowel Crohn's disease.
   Eur J Gastroenterol Hepatol. 2026;38:442-449.
   PubMed     Abstract available
   
   
   
10. COELHO RODRIGUES I, Fernandes SR, Saraiva S, Goncalves AR, et al
    Fecal calprotectin-guided treatment escalation strategy enhances disease clearance in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026;38:431-436.
    PubMed     Abstract available
    
    
    March 2026
11. RZETELNA H, Santo P, de Souza HSP, Nichols J, et al
    Positive conversion of latent tuberculosis screening in patients with inflammatory bowel disease on antitumor necrosis factor alpha drugs: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2026 Mar 23. doi: 10.1097/MEG.0000000000003180.
    PubMed     Abstract available
    
    
    
12. DEYHIM T, Saraga A, Gade A, Geeganage G, et al
    Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Mar 23. doi: 10.1097/MEG.0000000000003183.
    PubMed     Abstract available
    
    
    
13. ZEWDU WS, Zerihun TE, Emiru ZA, Dagnew SB, et al
    Medication adherence level and its predictors among inflammatory bowel disease sufferers in a resource-strained healthcare setting.
    Eur J Gastroenterol Hepatol. 2026 Mar 6. doi: 10.1097/MEG.0000000000003166.
    PubMed     Abstract available
    
    
    
14. FOTEINOGIANNOPOULOU K, Nikolaou P, Orfanoudaki E, Theodoraki E, et al
    The rate and risk factors for malignancy in patients with inflammatory bowel disease in Crete: a case control study.
    Eur J Gastroenterol Hepatol. 2026;38:327-332.
    PubMed     Abstract available
    
    
    February 2026
15. OIWA K, Yamamura T, Nakamura M, Maeda K, et al
    Total biopsy via endoscopic submucosal dissection is useful for the diagnosis of neoplastic lesions in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026 Feb 26. doi: 10.1097/MEG.0000000000003165.
    PubMed     Abstract available
    
    
    
16. ANANDABASKARAN S, Liu Z, Hanna L, Lung P, et al
    Tissue penetration of anti-tumour necrosis factor therapy in perianal fistulising Crohn's disease: a proof-of-concept study.
    Eur J Gastroenterol Hepatol. 2026 Feb 24. doi: 10.1097/MEG.0000000000003169.
    PubMed     Abstract available
    
    
    
17. SLEUTJES JAM, van de Pol N, van der Meer AJ, de Man RA, et al
    Cardiovascular risk profiles in patients with primary sclerosing cholangitis.
    Eur J Gastroenterol Hepatol. 2026 Feb 23. doi: 10.1097/MEG.0000000000003146.
    PubMed     Abstract available
    
    
    
18. GUIMARAES A, Caetano AC, Barbosa I, Costa D, et al
    Validation of the Urgency Numeric Rating Scale and correlation with endoscopic, histological, and manometric activity in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026 Feb 10. doi: 10.1097/MEG.0000000000003155.
    PubMed     Abstract available
    
    
    January 2026
19. GALTS CPC, Anvari S, Haq M, Grossman K, et al
    Second-line infliximab therapy for ulcerative colitis (SLIT-UC): a retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2026 Jan 13. doi: 10.1097/MEG.0000000000003132.
    PubMed     Abstract available
    
    
    
20. NATHA C, Colli Cruz C, Vemulapalli V, Sullivan A, et al
    Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapy.
    Eur J Gastroenterol Hepatol. 2026 Jan 6. doi: 10.1097/MEG.0000000000003124.
    PubMed     Abstract available
    
    
    December 2025
21. TANG L, Mo J, Ouyang J, Li W, et al
    A multilevel analysis of the genetic association between inflammatory bowel disease and primary sclerosing cholangitis.
    Eur J Gastroenterol Hepatol. 2025 Dec 9. doi: 10.1097/MEG.0000000000003116.
    PubMed     Abstract available
    
    
    
22. BEVIVINO G, Scarozza P, Zerboni G, Iacopini F, et al
    Infliximab-induced pulmonary interstitial disease in a male patient with ulcerative colitis: a case report and review of literature.
    Eur J Gastroenterol Hepatol. 2025;37:1402-1405.
    PubMed     Abstract available
    
    
    November 2025
23. BUCHNER AM, Kohen R, Sonnenberg A
    Epstein-Barr virus infection increases the risk for inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Nov 26. doi: 10.1097/MEG.0000000000003109.
    PubMed     Abstract available
    
    
    
24. SUN Z, Zhu Z, Yang R, Cao L, et al
    Correlation between infliximab trough levels and postoperative endoscopic recurrence in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2025 Nov 5. doi: 10.1097/MEG.0000000000003088.
    PubMed     Abstract available
    
    
    October 2025
25. SILBER JL, Norman JM, Kanno T, Crossette EM, et al
    A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in he
    Eur J Gastroenterol Hepatol. 2025 Oct 23. doi: 10.1097/MEG.0000000000003098.
    PubMed     Abstract available
    
    
    
26. WONG ECL, Khan N, Dulai PS, Marshall JK, et al
    Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trial.
    Eur J Gastroenterol Hepatol. 2025 Oct 20. doi: 10.1097/MEG.0000000000003092.
    PubMed     Abstract available
    
    
    
27. VIAZIS N, Toruner M, Papastergiou V, Mousourakis K, et al
    Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study.
    Eur J Gastroenterol Hepatol. 2025 Oct 7. doi: 10.1097/MEG.0000000000003083.
    PubMed     Abstract available
    
    
    
28. BRAASCH T, Siegmund B
    The role of chest X-ray in latent tuberculosis infection screening for inflammatory bowel disease patients in low-incidence countries: in response to Gatt et al. (Eur J Gastroenterol Hepatol 2025;37:728-732).
    Eur J Gastroenterol Hepatol. 2025;37:1186.
    PubMed    
    
    
    September 2025
29. QIN Y, He C, Zhong N, Guo L, et al
    Exploring the molecular mechanism of Crohn's disease and rheumatoid arthritis: a bioinformatics and functional analysis approach.
    Eur J Gastroenterol Hepatol. 2025 Sep 8. doi: 10.1097/MEG.0000000000003068.
    PubMed     Abstract available
    
    
    
30. TAMIMI TA, Abu-Farsakh N, AlRyalat SA, Obeidat K, et al
    Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Sep 5. doi: 10.1097/MEG.0000000000003067.
    PubMed     Abstract available
    
    
    August 2025
31. PARKASH N, Keung C, Bell SJ, Moore GT, et al
    Evaluating the completeness of postoperative endoscopic recurrence assessment in Crohn's disease patients with Kono-S anastomoses.
    Eur J Gastroenterol Hepatol. 2025 Aug 25. doi: 10.1097/MEG.0000000000003063.
    PubMed     Abstract available
    
    
    
32. LU G, Sun J, Du H
    Feasibility and Preliminary Efficacy of combined home-based fecal calprotectin self-testing and therapeutic drug monitoring-guided intervention in Patients with moderate-to-severe inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Aug 15. doi: 10.1097/MEG.0000000000003061.
    PubMed     Abstract available
    
    
    
33. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
    Letter to the editor regarding 'First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn's disease'.
    Eur J Gastroenterol Hepatol. 2025;37:985-986.
    PubMed    
    
    
    
34. RIVA A, Arienti G, Zuin G, Spini L, et al
    Psychological symptoms and alexithymia in adolescents with inflammatory bowel diseases: a case-control study.
    Eur J Gastroenterol Hepatol. 2025;37:917-921.
    PubMed     Abstract available
    
    
    July 2025
35. MICALLEF S, Mintoff F, Ellul P, Sciberras M, et al
    Nourishing remission: the role of Crohn's disease exclusion diet and partial enteral nutrition in pregnancy: a comprehensive review.
    Eur J Gastroenterol Hepatol. 2025 Jul 22. doi: 10.1097/MEG.0000000000003050.
    PubMed     Abstract available
    
    
    
36. EALIWA N, Alamour W, Abu-Tailakh M, Eraki L, et al
    Clinical characteristics and long-term outcomes among inflammatory bowel disease patients of different ethnic groups: a case-control study.
    Eur J Gastroenterol Hepatol. 2025 Jul 18. doi: 10.1097/MEG.0000000000003047.
    PubMed     Abstract available
    
    
    
37. MANTAKA A, Apostolakis I, Domeyer PR, Sarafis P, et al
    Quality of care in inflammatory bowel disease from patient's perspective using QUOTE-IBD: a Greek multicenter prospective study.
    Eur J Gastroenterol Hepatol. 2025 Jul 14. doi: 10.1097/MEG.0000000000003031.
    PubMed     Abstract available
    
    
    
38. HUANG C, Czuber-Dochan W, Norton C
    Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study.
    Eur J Gastroenterol Hepatol. 2025 Jul 14. doi: 10.1097/MEG.0000000000003034.
    PubMed     Abstract available
    
    
    June 2025
39. DI PAOLO MC, Cassinotti A, Pagnini C, Ceccarelli L, et al
    Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists.
    Eur J Gastroenterol Hepatol. 2025 Jun 26. doi: 10.1097/MEG.0000000000003025.
    PubMed     Abstract available
    
    
    
40. PUGLIESE N, Bezzio C, Festa S, Caprioli FA, et al
    Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.
    Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003016.
    PubMed     Abstract available
    
    
    
41. COUTO SOUSA D, Fernandes SR, Saraiva S, Goncalves AR, et al
    Outcomes of acute severe ulcerative colitis at initial presentation.
    Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003015.
    PubMed     Abstract available
    
    
    
42. CROSEWSKI NI, Pereira AHM, Kotze LR, Pedroso MLA, et al
    Hepatotoxicity associated with vedolizumab: case report in a patient with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003022.
    PubMed     Abstract available
    
    
    May 2025
43. SCALVINI D, Bezzio C, Maimaris S, Lenti MV, et al
    A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.
    Eur J Gastroenterol Hepatol. 2025 May 19. doi: 10.1097/MEG.0000000000003005.
    PubMed     Abstract available
    
    
    
44. SZLAK J, Magdziak A, Mroz A, Wieszczy-Szczepanik P, et al
    Cytomegalovirus infection in patients with active ulcerative colitis: a prospective observational study.
    Eur J Gastroenterol Hepatol. 2025 May 12. doi: 10.1097/MEG.0000000000003001.
    PubMed     Abstract available
    
    
    
45. MORGAN M, Loel B, Lang R, Reilly C, et al
    The use of oral antibiotic cocktail in medically refractory paediatric acute severe colitis: a case series.
    Eur J Gastroenterol Hepatol. 2025;37:594-599.
    PubMed     Abstract available
    
    
    April 2025
46. COLWILL M, Baillie S, Radia C, White S, et al
    The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Apr 30. doi: 10.1097/MEG.0000000000002995.
    PubMed     Abstract available
    
    
    March 2025
47. GATT Y, Chatlani D, Camilleri C, Sciberras M, et al
    The role of chest X-ray in detecting latent tuberculosis among patients with low-risk inflammatory bowel disease before advanced therapy.
    Eur J Gastroenterol Hepatol. 2025 Mar 26. doi: 10.1097/MEG.0000000000002975.
    PubMed     Abstract available
    
    
    
48. PATRA S, Chaudhary S, Samal SC, Ayyanar P, et al
    FoxP3-positive T regulatory cells and its effector mechanisms in Crohn's disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies.
    Eur J Gastroenterol Hepatol. 2025 Mar 24. doi: 10.1097/MEG.0000000000002971.
    PubMed     Abstract available
    
    
    
49. YUKSEL I, Cagir Y, Durak MB, Atay A, et al
    A comparison between the Bowel Ultrasound Score and International Bowel Ultrasound Segmental Activity Score based on ileocolonoscopy in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2025 Mar 18. doi: 10.1097/MEG.0000000000002969.
    PubMed     Abstract available
    
    
    
50. GODOY FINGER AP, Tavares Ferreira de Oliveira Cruz L, Rosevics L, de Queiroz-Telles F, et al
    Management of sporotrichosis in patients with inflammatory bowel disease using biological therapy (antitumor necrosis factor).
    Eur J Gastroenterol Hepatol. 2025;37:370-375.
    PubMed     Abstract available
    
    
    
51. HANZEL J, Novak G, Jairath V, Zou G, et al
    Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot study.
    Eur J Gastroenterol Hepatol. 2025;37:304-307.
    PubMed     Abstract available
    
    
    
52. TE GROEN M, Derks MEW, Nagtegaal ID, Peters CP, et al
    Gastrointestinal pathologist consensus of revised high-grade dysplasia in inflammatory bowel disease impacts the advanced neoplasia rate: a multicenter study.
    Eur J Gastroenterol Hepatol. 2025;37:287-294.
    PubMed     Abstract available
    
    
    February 2025
53. JANSEN FM, den Broeder N, van Hal TW, Mahler EAM, et al
    Characteristics, risk factors, and disease course of musculoskeletal manifestations in patients with inflammatory bowel disease: a prospective longitudinal cohort study.
    Eur J Gastroenterol Hepatol. 2025 Feb 21. doi: 10.1097/MEG.0000000000002921.
    PubMed     Abstract available
    
    
    
54. OJAGHI SHIRMARD F, Pourfaraji SM, Saeedian B, Bagheri T, et al
    The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2025 Feb 18. doi: 10.1097/MEG.0000000000002952.
    PubMed     Abstract available
    
    
    
55. SUPOVEC E, Hanzel J, Novak G, Manevski D, et al
    First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2025 Feb 6. doi: 10.1097/MEG.0000000000002940.
    PubMed     Abstract available
    
    
    
56. MOLANDER P, Af Bjorkesten CG, Henricson H, Koskela R, et al
    Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study.
    Eur J Gastroenterol Hepatol. 2025 Feb 5. doi: 10.1097/MEG.0000000000002939.
    PubMed     Abstract available
    
    
    
57. BASSOTTI G, Del Sordo R, Lanzarotto F, Mino S, et al
    Claudin-2 simplifies histological assessment of activity/remission of ulcerative colitis in real-life daily practice.
    Eur J Gastroenterol Hepatol. 2025 Feb 4. doi: 10.1097/MEG.0000000000002938.
    PubMed     Abstract available
    
    
    
58. ZARKER AW, Wang Y
    Combination vedolizumab and ustekinumab for refractory Crohn's disease after immune checkpoint inhibitors.
    Eur J Gastroenterol Hepatol. 2025;37:240-241.
    PubMed    
    
    
    January 2025
59. LIATSOS C, Tzouvala M, Michalopoulos G, Giouleme O, et al
    Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.
    Eur J Gastroenterol Hepatol. 2025 Jan 23. doi: 10.1097/MEG.0000000000002926.
    PubMed     Abstract available
    
    
    
60. KOHLI I, Thind N, Bhalla A, Attri A, et al
    Sarcopenia is associated with worse outcomes in patients with inflammatory bowel disease: insights from US national hospitalization data.
    Eur J Gastroenterol Hepatol. 2025;37:55-61.
    PubMed     Abstract available
    
    
    
61. ALHALABI MM, Almokdad R
    The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis.
    Eur J Gastroenterol Hepatol. 2025;37:1-9.
    PubMed     Abstract available
    
    
    
62. ELFORD AT, Heldt R, Kamal S, Christensen B, et al
    Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2025;37:47-54.
    PubMed     Abstract available
    
    
    November 2024
63. ALBSHESH A, Abend A, Yehuda RM, Mahajna H, et al
    Intestinal ultrasound accurately predicts future therapy failure in Crohn's disease patients in a biologics-induced remission.
    Eur J Gastroenterol Hepatol. 2024 Nov 8. doi: 10.1097/MEG.0000000000002883.
    PubMed     Abstract available
    
    
    
64. KOPPELMAN LJM, Maljaars PWJ, Voorneveld PW, van der Meulen-de Jong AE, et al
    Healthcare utilisation patterns and drivers amongst inflammatory bowel disease patients in the outpatient clinic.
    Eur J Gastroenterol Hepatol. 2024 Nov 5. doi: 10.1097/MEG.0000000000002880.
    PubMed     Abstract available
    
    
    
65. SUN Z, Li Y
    After nonsurgical treatment of penetrating Crohn's disease: indications for subsequent surgical intervention.
    Eur J Gastroenterol Hepatol. 2024;36:1353-1354.
    PubMed    
    
    
    
66. DURAK MB
    Nonsurgical approach in penetrating Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024;36:1352.
    PubMed    
    
    
    
67. FERREIRA AI, Lima Capela T, Arieira C, Xavier S, et al
    Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Eur J Gastroenterol Hepatol. 2024;36:1314-1318.
    PubMed     Abstract available
    
    
    October 2024
68. SELIN KA, Andersson S, Bilen K, Strid H, et al
    Variation in nutritional therapy practices: results of a survey on nutritional management of severe inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1097/MEG.0000000000002872.
    PubMed     Abstract available
    
    
    
69. DAUNGSUPAWONG H, Wiwanitkit V
    Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet: correspondence.
    Eur J Gastroenterol Hepatol. 2024;36:1243.
    PubMed    
    
    
    September 2024
70. PAPATHANASIOU E, Kokkotis G, Axiaris G, Bellou G, et al
    Pregnancy outcomes in Greek women with inflammatory bowel disease: a longitudinal national retrospective study.
    Eur J Gastroenterol Hepatol. 2024 Sep 23. doi: 10.1097/MEG.0000000000002844.
    PubMed     Abstract available
    
    
    
71. SABHAN H, Bello F, Muhsen S, Borin A, et al
    Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE).
    Eur J Gastroenterol Hepatol. 2024 Sep 20. doi: 10.1097/MEG.0000000000002854.
    PubMed     Abstract available
    
    
    
72. CESARO N, Valvano M, Monaco S, Stefanelli G, et al
    The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2024 Sep 12. doi: 10.1097/MEG.0000000000002842.
    PubMed     Abstract available
    
    
    
73. ALDIABAT M, Alhuneafat L, Al Ta'ani O, Altarawneh S, et al
    Inflammatory bowel disease and pulmonary embolism: a nationwide perspective.
    Eur J Gastroenterol Hepatol. 2024 Sep 12. doi: 10.1097/MEG.0000000000002851.
    PubMed     Abstract available
    
    
    
74. LOW ES, Greeve T, Boyapati RK, Moore GT, et al
    Characteristics of the Kono-S anastomosis in Crohn's disease patients using intestinal ultrasound.
    Eur J Gastroenterol Hepatol. 2024;36:1150-1152.
    PubMed    
    
    
    
75. COELHO R, Goncalves R, Mendes F, Macedo G, et al
    Gastroenterology healthcare in LGBTQ+ individuals.
    Eur J Gastroenterol Hepatol. 2024;36:1059-1067.
    PubMed     Abstract available
    
    
    August 2024
76. DU J, Xu F, Qiu X, Hu X, et al
    A novel computed tomography enterography radiomics combining intestinal and creeping fat features could predict surgery risk in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Aug 23. doi: 10.1097/MEG.0000000000002839.
    PubMed     Abstract available
    
    
    
77. NEAMTI L, Drugan TC, Drugan C, Silaghi C, et al
    Assessing seasonal variations of biomarkers in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:993-999.
    PubMed     Abstract available
    
    
    July 2024
78. KAMEL AY, Johnson ZD, Hernandez I, Nguyen C, et al
    Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis.
    Eur J Gastroenterol Hepatol. 2024 Jul 16. doi: 10.1097/MEG.0000000000002821.
    PubMed     Abstract available
    
    
    
79. KHALAF R, Sciberras M, Ellul P
    The role of the fecal microbiota in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002818.
    PubMed     Abstract available
    
    
    
80. NAQVI HA, Delungahawatta T, Atarere JO, Bandaru SK, et al
    Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002815.
    PubMed     Abstract available
    
    
    
81. KOLEHMAINEN S, Rautakorpi J, Loyttyniemi E, Af Bjorkesten CG, et al
    Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002816.
    PubMed     Abstract available
    
    
    
82. MILIOLI NJ, Fernandes MV, Correa TL, Antunes V, et al
    Vedolizumab versus ustekinumab in Crohn's disease with prior anti-tumor necrosis factor failure: an updated meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Jul 2. doi: 10.1097/MEG.0000000000002817.
    PubMed     Abstract available
    
    
    
83. OZTURK O, Celebi G, Duman UG, Kupcuk E, et al
    Short-chain fatty acid levels in stools of patients with inflammatory bowel disease are lower than those in healthy subjects.
    Eur J Gastroenterol Hepatol. 2024;36:890-896.
    PubMed     Abstract available
    
    
    June 2024
84. TORIS LD, Minsart CF, Husson CP, Franchimont DP, et al
    Lipopolysaccharide-binding protein in Crohn's disease patients: a promising noninvasive biomarker monitoring disease activity.
    Eur J Gastroenterol Hepatol. 2024 Jun 26. doi: 10.1097/MEG.0000000000002811.
    PubMed     Abstract available
    
    
    
85. FIERENS L, Bossuyt P, Baert F, Baert D, et al
    Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jun 19. doi: 10.1097/MEG.0000000000002804.
    PubMed     Abstract available
    
    
    
86. CHHIBBA T, Wong ECL, Reinisch W, Targownik L, et al
    Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.
    Eur J Gastroenterol Hepatol. 2024;36:704-711.
    PubMed     Abstract available
    
    
    May 2024
87. FREEMAN HJ
    Osteonecrosis (avascular necrosis) in inflammatory bowel disease: an extraintestinal clinical feature, not caused by corticosteroids.
    Eur J Gastroenterol Hepatol. 2024;36:503-504.
    PubMed    
    
    
    April 2024
88. YUAN B, Huang P, Yang M, Tang G, et al
    Intestinal ultrasound scan predicts corticosteroid failure and colectomy risk in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2024 Apr 17. doi: 10.1097/MEG.0000000000002780.
    PubMed     Abstract available
    
    
    
89. WESTON F, Carter B, Powell N, Young AH, et al
    Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002768.
    PubMed     Abstract available
    
    
    
90. SUN Z, Cao L, Chen Y, Zhu W, et al
    Long-term outcomes of intestinal penetrating Crohn's disease following successful nonoperative management.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002775.
    PubMed     Abstract available
    
    
    
91. TEPES K, Hanzel J, Stubljar D, Strmsek K, et al
    Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Eur J Gastroenterol Hepatol. 2024 Apr 2. doi: 10.1097/MEG.0000000000002771.
    PubMed     Abstract available
    
    
    
92. D'HAENS G, Baert F, Danese S, Kobayashi T, et al
    Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    Eur J Gastroenterol Hepatol. 2024;36:404-415.
    PubMed     Abstract available
    
    
    
93. BAI Y, Sun Y, He Q, Bai X, et al
    Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024;36:359-370.
    PubMed     Abstract available
    
    
    
94. KOSTEV K, Roderburg C, Loosen SH
    Inflammatory bowel disease is associated with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2024;36:498.
    PubMed    
    
    
    March 2024
95. ZAGOROWICZ E, Binowski G, Strzadala D, Pruszko C, et al
    Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland.
    Eur J Gastroenterol Hepatol. 2024 Mar 19. doi: 10.1097/MEG.0000000000002764.
    PubMed     Abstract available
    
    
    
96. ROKKAS T, Gisbert JP, Ekmektzoglou K, Dassopoulos T, et al
    Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Mar 12. doi: 10.1097/MEG.0000000000002751.
    PubMed     Abstract available
    
    
    
97. STEPHENS IJB, Murphy B, Burns L, McCawley N, et al
    Contemporary perioperative outcomes after total abdominal colectomy for ulcerative colitis in a tertiary referral centre.
    Eur J Gastroenterol Hepatol. 2024 Mar 11. doi: 10.1097/MEG.0000000000002755.
    PubMed     Abstract available
    
    
    
98. MOGILEVSKI T, Nguyen AL, Ajamian M, Smith R, et al
    Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:271-280.
    PubMed     Abstract available
    
    
    
99. FIORINO G, Colombel JF, Katsanos K, Mearin F, et al
    Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy.
    Eur J Gastroenterol Hepatol. 2024 Mar 1. doi: 10.1097/MEG.0000000000002740.
    PubMed     Abstract available
    
    
    February 2024
100. BHAYANA H, Sharma TK, Sharma A, Dhillon MS, et al
     Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis.
     Eur J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1097/MEG.0000000000002735.
     PubMed     Abstract available
     
     
     January 2024
101. KIRKIK D, Kalkanli Tas S, Tanoglu A
     Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn's disease.
     Eur J Gastroenterol Hepatol. 2024 Jan 22. doi: 10.1097/MEG.0000000000002695.
     PubMed     Abstract available
     
     
     December 2023
102. MANTZARIS GJ, Bressler B, Adsul S, Luo M, et al
     Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
     Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002690.
     PubMed     Abstract available
     
     
     
103. VIAZIS N, Manolakis A, Vraka M, Mylonas I, et al
     Anal defecatory function in ulcerative colitis patients after total proctocolectomy and ileal pouch-anal anastomosis: a prospective cohort study.
     Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002706.
     PubMed     Abstract available
     
     
     
104. SONNENBERG A, Duong HT, McCarty DJ, El-Serag HB, et al
     Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma.
     Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
     PubMed     Abstract available
     
     
     
105. STJARNGRIM J, Ekbom A, Widman L, Hultcrantz R, et al
     Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease 2001-2015: a population-based case review study.
     Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
     PubMed     Abstract available
     
     
     November 2023
106. NGUYEN AL, Herath M, Burns M, Holt D, et al
     The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study.
     Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
     PubMed     Abstract available
     
     
     October 2023
107. LIU C, Liu X, Shi H, Chen F, et al
     The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis.
     Eur J Gastroenterol Hepatol. 2023 Oct 18. doi: 10.1097/MEG.0000000000002670.
     PubMed     Abstract available
     
     
     
108. BARAUNA FSB, Magro DO, Miranda EF, Marcal GN, et al
     Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.
     Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002639.
     PubMed     Abstract available
     
     
     
109. VALIBOUZE C, Nachury M, Hambli S, Desreumaux P, et al
     Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2023;35:1230.
     PubMed    
     
     
     
110. JANSEN FM, den Broeder N, Lubeek SFK, Savelkoul EHJ, et al
     Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study.
     Eur J Gastroenterol Hepatol. 2023;35:1123-1130.
     PubMed     Abstract available
     
     
     September 2023
111. FERRARO S, Cappello E, Bartolini C, Convertino I, et al
     Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
     Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002642.
     PubMed     Abstract available
     
     
     
112. ALHALABI M, Alaa Eddin K, Abbas A
     Therapeutic effects of biological treatments on AA amyloidosis associated with inflammatory bowel disease: a case report and literature review.
     Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002649.
     PubMed     Abstract available
     
     
     
113. HONAP S, Irving PM, Samaan MA
     JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice.
     Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002650.
     PubMed     Abstract available
     
     
     
114. NERI B, D'Agostini G, Salvatori S, Mossa M, et al
     Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
     Eur J Gastroenterol Hepatol. 2023;35:948-954.
     PubMed     Abstract available
     
     
     August 2023
115. ZHANG T, Zhang QD, Jin T, Li WJ, et al
     Is histological healing more clinically valuable than endoscopic healing in Crohn's disease?
     Eur J Gastroenterol Hepatol. 2023 Aug 14. doi: 10.1097/MEG.0000000000002624.
     PubMed     Abstract available
     
     
     
116. TSAFARIDOU M, Augoustaki A, Koutroubakis I
     Lymphogranuloma venereum and CMV co-infection mimicking ulcerative proctitis in a non-immunocompromised patient.
     Eur J Gastroenterol Hepatol. 2023;35:921-922.
     PubMed    
     
     
     
117. HUANG Y, Su Y, Qin R, Wang L, et al
     Mechanism by which oleracein E alleviates TNBS-induced ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2023;35:854-864.
     PubMed     Abstract available
     
     
     July 2023
118. LYKOWSKA-SZUBER L, Walczak M, Dobrowolska A, Skrzypczak-Zielinska M, et al
     Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn's disease patients.
     Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002618.
     PubMed     Abstract available
     
     
     
119. ZHAN Y, Cheng X, Mei P, Wu J, et al
     Risk and incidence of colorectal stricture progressing to colorectal neoplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
     Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002614.
     PubMed     Abstract available
     
     
     
120. BOUSTANY A, Rahhal R, Mitri J, Onwuzo S, et al
     The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
     Eur J Gastroenterol Hepatol. 2023 Jul 11. doi: 10.1097/MEG.0000000000002607.
     PubMed     Abstract available
     
     
     May 2023
121. KONSTANTINOU CS, Korantzopoulos P, Fousekis FS, Katsanos KH, et al
     Inflammatory bowel disease and atrial fibrillation: a contemporary overview.
     Eur J Gastroenterol Hepatol. 2023 May 8. doi: 10.1097/MEG.0000000000002562.
     PubMed     Abstract available
     
     
     
122. HASSAN EA, Abdel Rehim ASE, Ahmed AO, Salim SMAE, et al
     Current insight into enteropathogens in flare-up ulcerative colitis. An observational study.
     Eur J Gastroenterol Hepatol. 2023 May 3. doi: 10.1097/MEG.0000000000002563.
     PubMed     Abstract available
     
     
     
123. PRENTICE RE, Wright EK, Flanagan E, Kamm MA, et al
     Evaluation and management of ileal pouch-anal anastamosis (IPAA) complications in pregnancy, and the impacts of an IPAA on fertility.
     Eur J Gastroenterol Hepatol. 2023;35:609-612.
     PubMed     Abstract available
     
     
     April 2023
124. CHAHAL JK, Sriranganathan D, Poo S, Lo SW, et al
     Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease.
     Eur J Gastroenterol Hepatol. 2023 Apr 11. doi: 10.1097/MEG.0000000000002552.
     PubMed     Abstract available
     
     
     
125. PRINCIPI M, Macaluso FS, Todeschini A, Facciotti F, et al
     Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
     Eur J Gastroenterol Hepatol. 2023 Apr 4. doi: 10.1097/MEG.0000000000002550.
     PubMed     Abstract available
     
     
     March 2023
126. NOVAK G, Sever N, Hanzel J, Kozelj M, et al
     Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2023 Mar 20. doi: 10.1097/MEG.0000000000002543.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum